Copyright Reports & Markets. All rights reserved.

Europe Urology Drugs Market Report 2018

Buy now

Table of Contents

    1 Report Overview

    • 1.1 Definition and Specification
    • 1.2 Report Overview
      • 1.2.1 Manufacturers Overview
      • 1.2.2 Regions Overview
      • 1.2.3 Type Overview
      • 1.2.4 Application Overview
    • 1.3 Industrial Chain
      • 1.3.1 Urology Drugs Overall Industrial Chain
      • 1.3.2 Upstream
      • 1.3.3 Downstream
    • 1.4 Industry Situation
      • 1.4.1 Industrial Policy
      • 1.4.2 Product Preference
      • 1.4.3 Economic/Political Environment
    • 1.5 SWOT Analysis

    2 Market Analysis by Types

    • 2.1 Overall Market Performance(Volume)
      • 2.1.1 α (alpha) - blockers Market Performance (Volume)
      • 2.1.2 5 α-reductase inhibitors Market Performance (Volume)
    • 2.2 Overall Market Performance(Value)
      • 2.1.1 α (alpha) - blockers Market Performance (Value)
      • 2.1.2 5 α-reductase inhibitors Market Performance (Value)

    3 Product Application Market

    • 3.1 Overall Market Performance (Volume)
      • 3.1.1 Hospital Market Performance (Volume)
      • 3.1.2 Clinic Market Performance (Volume)

    4 Manufacturers Profiles/Analysis

    • 4.1 Astellas
      • 4.1.1 Astellas Profiles
      • 4.1.2 Astellas Product Information
      • 4.1.3 Astellas Urology Drugs Business Performance
      • 4.1.4 Astellas Urology Drugs Business Development and Market Status
    • 4.2 Endo
      • 4.2.1 Endo Profiles
      • 4.2.2 Endo Product Information
      • 4.2.3 Endo Urology Drugs Business Performance
      • 4.2.4 Endo Urology Drugs Business Development and Market Status
    • 4.3 GP Pharm
      • 4.3.1 GP Pharm Profiles
      • 4.3.2 GP Pharm Product Information
      • 4.3.3 GP Pharm Urology Drugs Business Performance
      • 4.3.4 GP Pharm Urology Drugs Business Development and Market Status
    • 4.4 Tolmar
      • 4.4.1 Tolmar Profiles
      • 4.4.2 Tolmar Product Information
      • 4.4.3 Tolmar Urology Drugs Business Performance
      • 4.4.4 Tolmar Urology Drugs Business Development and Market Status

    5 Market Performance for Manufacturers

    • 5.1 Europe Urology Drugs Sales (K Units) and Market Share by Manufacturers 2013-2018
    • 5.2 Europe Urology Drugs Revenue (M USD) and Market Share by Manufacturers 2013-2018
    • 5.3 Europe Urology Drugs Price (USD/Unit) of Manufacturers 2013-2018
    • 5.4 Europe Urology Drugs Gross Margin of Manufacturers 2013-2018
    • 5.5 Market Concentration

    6 Regions Market Performance for Manufacturers

    • 6.1 Germany Market Performance for Manufacturers
      • 6.1.1 Germany Urology Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.1.2 Germany Urology Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.1.3 Germany Urology Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.1.4 Germany Urology Drugs Gross Margin of Manufacturers 2013-2018
      • 6.1.5 Market Concentration
    • 6.2 UK Market Performance for Manufacturers
      • 6.2.1 UK Urology Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.2.2 UK Urology Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.2.3 UK Urology Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.2.4 UK Urology Drugs Gross Margin of Manufacturers 2013-2018
      • 6.2.5 Market Concentration
    • 6.3 France Market Performance for Manufacturers
      • 6.3.1 France Urology Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.3.2 France Urology Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.3.3 France Urology Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.3.4 France Urology Drugs Gross Margin of Manufacturers 2013-2018
      • 6.3.5 Market Concentration
    • 6.4 Russia Market Performance for Manufacturers
      • 6.4.1 Russia Urology Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.4.2 Russia Urology Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.4.3 Russia Urology Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.4.4 Russia Urology Drugs Gross Margin of Manufacturers 2013-2018
      • 6.4.5 Market Concentration
    • 6.5 Benelux Market Performance for Manufacturers
      • 6.5.1 Benelux Urology Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.5.2 Benelux Urology Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.5.3 Benelux Urology Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.5.4 Benelux Urology Drugs Gross Margin of Manufacturers 2013-2018
      • 6.5.5 Market Concentration
    • 6.6 Italy Market Performance for Manufacturers
      • 6.6.1 Italy Urology Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.6.2 Italy Urology Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.6.3 Italy Urology Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.6.4 Italy Urology Drugs Gross Margin of Manufacturers 2013-2018
      • 6.6.5 Market Concentration
    • 6.7 Spain Market Performance for Manufacturers
      • 6.7.1 Spain Urology Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.7.2 Spain Urology Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.7.3 Spain Urology Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.7.4 Spain Urology Drugs Gross Margin of Manufacturers 2013-2018
      • 6.7.5 Market Concentration
    • 6.8 Market Performance for Manufacturers
      • 6.8.1 Urology Drugs Sales (K Units) and Share of Manufacturers 2013-2018
      • 6.8.2 Urology Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
      • 6.8.3 Urology Drugs Price (USD/Unit) of Manufacturers 2013-2018
      • 6.8.4 Urology Drugs Gross Margin of Manufacturers 2013-2018
      • 6.8.5 Market Concentration

    7 Europe Urology Drugs Market Performance (Sales Point)

    • 7.1 Europe Urology Drugs Sales (K Units) and Market Share by Regions 2013-2018
    • 7.2 Europe Urology Drugs Revenue (M USD) and Market Share by Regions 2013-2018
    • 7.3 Europe Urology Drugs Price (USD/Unit) by Regions 2013-2018
    • 7.4 Europe Urology Drugs Gross Margin by Regions 2013-2018

    8 Development Trend for Regions (Sales Point)

    • 8.1 Europe Urology Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.2 Germany Urology Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.3 UK Urology Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.4 France Urology Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.5 Russia Urology Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.6 Benelux Urology Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.7 Italy Urology Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.8 Spain Urology Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
    • 8.8 Spain Urology Drugs Sales and Growth, Sales Value and Growth Rate2013-2018

    9 Upstream Source, Technology and Cost

    • 9.1 Upstream Source
    • 9.2 Technology
    • 9.3 Cost

    10 Channel Analysis

    • 10.1 Market Channel
    • 10.2 Distributors

    11 Consumer Analysis

    • 11.1 Hospital Industry
    • 11.2 Clinic Industry

    12 Market Forecast 2019-2024

    • 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
      • 12.1.1 Europe Urology Drugs Sales (K Units), Revenue (M USD) and Market Share by Regions 2019-2024
      • 12.1.2 Europe Urology Drugs Sales (K Units) and Growth Rate 2019-2024
      • 12.1.3 Germany Urology Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.4 UK Urology Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.5 France Urology Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.6 Russia Urology Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.7 Benelux Urology Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.8 Italy Urology Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.1.9 Spain Urology Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
    • 12.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
      • 12.3.1 Overall Market Performance
      • 12.3.2 α (alpha) - blockers Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
      • 12.3.3 5 α-reductase inhibitors Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
    • 12.4 Sales by Application 2019-2024
      • 12.4.1 Overall Market Performance
      • 12.4.2 Hospital Sales and and Growth Rate 2019-2024
      • 12.4.3 Clinic Sales and and Growth Rate 2019-2024
    • 12.5 Price (USD/Unit) and Gross Profit
      • 12.5.1 Europe Urology Drugs Price (USD/Unit) Trend 2019-2024
      • 12.5.2 Europe Urology Drugs Gross Profit Trend 2019-2024

    13 Conclusion

    Geographically, this report split Europe into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Urology Drugs for these regions, from 2012 to 2023 (forecast), including
    Germany
    UK
    France
    Russia
    Benelux
    Italy
    Spain

    Europe Urology Drugs market competition by top manufacturers/players, with Urology Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Astellas
    Endo
    GP Pharm
    Tolmar
    ...

    On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
    α (alpha) - blockers
    5 α-reductase inhibitors

    On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Urology Drugs for each application, including
    Hospital
    Clinic

    If you have any special requirements, please let us know and we will offer you the report as you want.

    Buy now